Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 3/20 | 0.42 |
| ▸ | TK1 | P04183 | 2/20 | 0.41 |
| ▸ | TOP2A | P11388 | 3/20 | 0.39 |
| ▸ | TYMP | P19971 | 3/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065021 | 1.00 | TK2 (0.42) | TK2TK1TOP2ATYMPP2RY6 | |
| SCHEMBL19812217 | 0.93 | TK2 (0.47) | TK2TK1TOP2ATYMP | |
| SCHEMBL261288 | 0.93 | TK2 (0.47) | TK2TK1TOP2ATYMP | |
| SCHEMBL261289 | 0.93 | TK2 (0.47) | TK2TK1TOP2ATYMP | |
| SCHEMBL7247156 | 0.92 | TK2 (0.41) | TK2TK1TOP2ATYMP | |
| SCHEMBL313035 | 0.92 | TK2 (0.41) | TK2TK1TOP2ATYMP | |
| SCHEMBL260669 | 0.92 | TK2 (0.41) | TK2TK1TOP2ATYMP | |
| SCHEMBL1738120 | 0.91 | TYMP (0.41) | TK2TK1TOP2ATYMP | |
| SCHEMBL1738118 | 0.91 | TYMP (0.41) | TK2TK1TOP2ATYMP | |
| SCHEMBL15216189 | 0.90 | TK2 (0.41) | TK2TK1TOP2ATYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624294-B2 | Dissolving nucleoside in solvent to form a solution; cooling; treating with base; warming; reacting with ester to effect alkylation of 2' position of a 2',3'-dihydroxy sugar moiety of a nucleoside | ISIS PHARMACEUTICALS, INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030078415-A1 | Regioselective synthesis of 2'-O-modified nucleosides | IONIS PHARMACEUTICALS, INC. | 2003-04-24 | — | — | US | disclosed |
| US-6403779-B1 | DISSOLVING NUCLEOSIDE IN APROTIC SOLVENT, COOLING, TREATING WITH BASE, WARMING MIXTURE, COOLING, REACTING WITH REACTIVE ESTER TO EFFECT ALKYLATION | ISIS PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078415-A1 | Regioselective synthesis of 2'-O-modified nucleosides | NSUN2, NT5C3B, RNGTT | TK2 203/4885TK1 228/4885TOP2A 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.